You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Boehringer Ingelheim
Mallinckrodt
Colorcon

Last Updated: July 16, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NASONEX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Nasonex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00070707 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) Terminated Integrated Therapeutics Group Phase 4 2003-04-01 An association between seasonal allergic rhinitis (SAR) and allergic asthma has been established through epidemiologic, pathophysiologic, and therapeutic studies. This study will compare Nasonex Nasal Spray to Placebo in treating the nasal and asthma symptoms experienced by subjects with SAR and concomitant asthma.
NCT00070707 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) Terminated Merck Sharp & Dohme Corp. Phase 4 2003-04-01 An association between seasonal allergic rhinitis (SAR) and allergic asthma has been established through epidemiologic, pathophysiologic, and therapeutic studies. This study will compare Nasonex Nasal Spray to Placebo in treating the nasal and asthma symptoms experienced by subjects with SAR and concomitant asthma.
NCT00117611 Xolair in Patients With Chronic Sinusitis Completed Genentech, Inc. Phase 4 2005-07-01 The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
NCT00117611 Xolair in Patients With Chronic Sinusitis Completed Novartis Pharmaceuticals Phase 4 2005-07-01 The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
NCT00117611 Xolair in Patients With Chronic Sinusitis Completed University of Chicago Phase 4 2005-07-01 The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
NCT00224523 Long Term Safety Of GW685698X Via Nasal Biopsy Completed GlaxoSmithKline Phase 3 2005-09-01 Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nasonex

Condition Name

Condition Name for Nasonex
Intervention Trials
Allergic Rhinitis 9
Seasonal Allergic Rhinitis 9
Asthma 5
Rhinitis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nasonex
Intervention Trials
Rhinitis 31
Rhinitis, Allergic 27
Rhinitis, Allergic, Seasonal 15
Sinusitis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nasonex

Trials by Country

Trials by Country for Nasonex
Location Trials
United States 67
Canada 2
Belgium 2
Argentina 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nasonex
Location Trials
Texas 6
Illinois 5
Colorado 3
California 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nasonex

Clinical Trial Phase

Clinical Trial Phase for Nasonex
Clinical Trial Phase Trials
Phase 4 14
Phase 3 22
Phase 2 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nasonex
Clinical Trial Phase Trials
Completed 31
Terminated 5
Not yet recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nasonex

Sponsor Name

Sponsor Name for Nasonex
Sponsor Trials
Merck Sharp & Dohme Corp. 20
Schering-Plough 3
University of Chicago 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nasonex
Sponsor Trials
Industry 44
Other 11
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Colorcon
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.